Wedbush Reiterates Buy Rating for Kiniksa Pharmaceuticals
Wedbush maintains its buy rating on Kiniksa Pharmaceuticals with a $72 price target, a 12.59% upside from the current price.
Key Points
- Wedbush reiterated its buy rating for Kiniksa Pharmaceuticals on June 29, 2026, with a price target of $72.
- Wedbush's $72 price target implies 12.59% upside from Kiniksa Pharmaceuticals International, plc's ($KNSA) current $63.95 share price.
- Shares of NasdaqGS:KNSA traded at $62.41 on Wednesday, with a market cap of approximately $4.92 billion.
- Kiniksa Pharmaceuticals, a biopharmaceutical company, has a strong buy consensus with an average target price of $65.13.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Wedbush has reaffirmed its confidence in Kiniksa Pharmaceuticals International, plc (NasdaqGS:KNSA), reiterating a buy rating and setting a price target of $72. This update was announced on June 29, 2026, by analyst David Nierengarten. Shares of Kiniksa traded at $62.41 on Wednesday.
Wedbush vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Kiniksa Pharmaceuticals International, plc Stock Down 18.1%
Kiniksa Pharmaceuticals, listed on NasdaqGS under the ticker KNSA, saw its shares trade at $62.41 on Wednesday. The company has a market capitalization of roughly $4.92 billion and a P/E ratio of 70.3. Its stock has a 52-week range between $26.27 and $64.81, with a 50-day moving average of $52.60 and a 200-day moving average of $44.67. The company boasts a beta of 0.12, indicating low volatility, and has a current ratio of 3.79, reflecting strong liquidity.
$KNSA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its most recent earnings report, Kiniksa Pharmaceuticals posted revenue of about $754 million, demonstrating a growth rate of 55.5%. The company achieved a net margin of 9.7% and a return on equity of 13.7%, with an earnings per share (EPS) of $0.91. The next earnings report is expected on July 28, 2026.
Insider Buying and Selling at Kiniksa Pharmaceuticals International, plc
Recent insider activity at Kiniksa Pharmaceuticals includes transactions by Chairman and CEO Sanj Patel, who sold 900,000 shares on June 1, 2026, without a specified price. Richard Levy, another insider, bought 2,799 shares on May 29, 2026, while Thomas Malley purchased 12,158 shares on the same day. These transactions were not planned under Rule 10b5-1.
Analysts Set New Price Targets
On June 29, 2026, Wedbush maintained its buy rating for Kiniksa Pharmaceuticals with a $72 price target. Other analysts, such as Canaccord Genuity and Citigroup, have also maintained buy ratings with targets of $64 and $60, respectively, as of April 29, 2026. The consensus among analysts is a strong buy, with an average target price of $65.13 based on eight opinions.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company based in London, United Kingdom. It focuses on developing and commercializing therapies for cardiovascular and inflammatory diseases. The company markets ARCALYST, a treatment for recurrent pericarditis, and is advancing other pipeline products like KPL-387 and KPL-116. Founded in 2015, it operates in the United States, the United Kingdom, and globally under the leadership of CEO Mark A. Ragosa.
Bottom Line
Investors keep a close eye on Kiniksa Pharmaceuticals due to its promising pipeline and strong financial performance. The reiterated buy rating from Wedbush with a $72 target reflects continued confidence in the company's potential. As always, 13F filings and analyst updates like these are backward-looking and may not represent current positions or opinions.
Get Kiniksa Pharmaceuticals International, plc alerts
New 13F filings, insider trades, and analyst moves on $KNSA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.